Cardiac troponin-i on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. experience of the french thrombotic microangiopathies reference center

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 2, 2015, Pages 293-302

  Benhamou, Y ^a,b,c   Boelle, P Y ^d,e   Baudin, B ^c,e   Ederhy, S ^c,e   Gras, J ^c   Galicier, L ^c,f,g   Azoulay, E ^c,f,g   Provot F ^c,h   Maury, E ^c,e   Pene F ^c,g,i   Mira, J P ^c,g,i   Wynckel, A ^c,j   Presne, C ^c,k   Poullin, P ^c,l   Halimi, J M ^c,m,n   Delmas, Y ^c,o   Kanouni, T ^c,p   Seguin, A ^c,q   Mousson, C ^c,r   Servais, A ^c,s   Bordessoule, D ^c,t   Perez, P ^c,u   Hamidou, M ^c,v   Cohen, A ^c,e   Veyradier, A ^c,w,x   Coppo, P ^c,y   more..

^a HÔPITAL CHARLES NICOLLE   (France)

^b Université Normandie de Rouen   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d INSERM   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ Hôpital Maison Blanche ^*  (France)

^j HÔPITAL MAISON BLANCHE   (France)

^k AMIENS UNIVERSITY HOSPITAL   (France)

^l HÔPITAL DE LA CONCEPTION   (France)

^m CHU BRETONNEAU   (France)

ⁿ FHU SUPORT   (France)

^o BORDEAUX UNIVERSITY HOSPITAL   (France)

^p MONTPELLIER UNIVERSITY HOSPITAL   (France)

^q CAEN UNIVERSITY HOSPITAL   (France)

^r DIJON UNIVERSITY HOSPITAL   (France)

^s HÔPITAL NECKER ENFANTS MALADES   (France)

^t DUPUYTREN UNIVERSITY HOSPITAL   (France)

^u CHU NANCY BRABOIS   (France)

^v HÔTEL DIEU   (France)

^w HÔPITAL ANTOINE BÉCLÈRE   (France)

^x UNIVERSITÉ PARIS SACLAY   (France)

^y INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

ADAMTS13 protein, human; Prognosis; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura; Troponin

Indexed keywords

ANTITHROMBOCYTIC AGENT; CREATININE; FOLIC ACID; LACTATE DEHYDROGENASE; RITUXIMAB; TROPONIN I; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; BIOLOGICAL MARKER;

ADULT; ARTICLE; BRAIN HEMORRHAGE; CARDIOGENIC SHOCK; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; ELECTROCARDIOGRAM; FAINTNESS; FEMALE; GLOMERULUS FILTRATION RATE; HEART ARREST; HEART INFARCTION; HUMAN; MALE; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; AGED; BLOOD; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPLICATION; DEFICIENCY; ELECTROCARDIOGRAPHY; EVALUATION STUDY; FRANCE; GENETICS; HEART DISEASES; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PROGNOSIS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REGISTER; RISK; RISK FACTOR; STATISTICAL MODEL; TIME; UPREGULATION;

ADAM PROTEINS; ADULT; AGED; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; ELECTROCARDIOGRAPHY; FEMALE; FRANCE; HEART DISEASES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REGISTRIES; RISK FACTORS; TIME FACTORS; TROPONIN I; UP-REGULATION;

EID: 84922919803     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12790     Document Type: Article

References (35)

1. Coppo P, Veyradier A. Thrombotic microangiopathies: towards a pathophysiology-based classification. Cardiovasc Hematol Disord Drug Targets 2009; 9: 36-50.
2. Tsai HM. Autoimmune thrombotic microangiopathy: advances in pathogenesis, diagnosis, and management. Semin Thromb Hemost 2012; 38: 469-82.
3. Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, Machin SJ. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011; 118: 1746-53.
4. Froissart A, Buffet M, Veyradier A, Poullin P, Provôt F, Malot S, Schwarzinger M, Galicier L, Vanhille P, Vernant JP, Bordessoule D, Guidet B, Azoulay E, Mariotte E, Rondeau E, Mira JP, Wynckel A, Clabault K, Choukroun G, Presne C, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med 2012; 40: 104-11.
5. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991; 325: 393-7.
6. George JN. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354: 1927-35.
7. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. N Engl J Med 1991; 325: 398-403.
8. Coppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, Presne C, Poullin P, Malot S, Vanhille P, Azoulay E, Galicier L, Lemiale V, Mira JP, Ridel C, Rondeau E, Pourrat J, Girault S, Bordessoule D, Saheb S, Ramakers M, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS ONE 2010; 5: e10208.
9. Benhamou Y, Assié C, Boelle PY, Buffet M, Grillberger R, Malot S, Wynckel A, Presne C, Choukroun G, Poullin P, Provôt F, Gruson D, Hamidou M, Bordessoule D, Pourrat J, Mira JP, Le Guern V, Pouteil-Noble C, Daubin C, Vanhille P, et al. Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA reference center experience. Haematologica 2012; 97: 1181-6.
10. Patschan D, Witzke O, Duhrsen U, Erbel R, Philipp T, Herget-Rosenthal S. Acute myocardial infarction in thrombotic microangiopathies - clinical characteristics, risk factors and outcome. Nephrol Dial Transplant 2006; 21: 1549-54.
11. Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med 2003; 127: 834-9.
12. Ridolfi RL, Bell WR. Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature. Medicine (Baltimore) 1981; 60: 413-28.
13. Ridolfi RL, Hutchins GM, Bell WR. The heart and cardiac conduction system in thrombotic thrombocytopenic purpura. A clinicopathologic study of 17 autopsied patients. Ann Intern Med 1979; 91: 357-63.
14. Hawkins BM, Abu-Fadel M, Vesely SK, George JN. Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. Transfusion 2008; 48: 382-92.
15. Siersema PD, Kros JM, Van Den Berg B. Cardiac manifestations of thrombotic thrombocytopenic purpura. Neth J Med 1989; 35: 100-7.
16. Podolsky SH, Zembowicz A, Schoen FJ, Benjamin RJ, Sonna LA. Massive myocardial necrosis in thrombotic thrombocytopenic purpura: a case report and review of the literature. Arch Pathol Lab Med 1999; 123: 937-40.
17. James TN, Monto RW. Pathology of the cardiac conduction system in thrombotic thrombocytopenic purpura. Ann Intern Med 1966; 65: 37-43.
18. Gami AS, Hayman SR, Grande JP, Garovic VD. Incidence and prognosis of acute heart failure in the thrombotic microangiopathies. Am J Med 2005; 118: 544-7.
19. Gandhi K, Aronow WS, Desai H, Amin H, Sharma M, Lai HM, Singh P. Cardiovascular manifestations in patients with thrombotic thrombocytopenic purpura: a single-center experience. Clin Cardiol 2010; 33: 213-16.
20. Wahla AS, Ruiz J, Noureddine N, Upadhya B, Sane DC, Owen J. Myocardial infarction in thrombotic thrombocytopenic purpura: a single-center experience and literature review. Eur J Haematol 2008; 81: 311-16.
21. Peacock WF 4th, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, Wu AH; ADHERE Investigators. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008; 358: 2117-26.
22. Hughes C, McEwan JR, Longair I, Hughes S, Cohen H, Machin S, Scully M. Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13. J Thromb Haemost 2009; 7: 529-36.
23. Kremer HJ, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115: 1500-11; quiz 1662.
24. Coppo P, Veyradier A. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura. Presse Med 2012; 41: e163-76.
25. Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, Cheung B, Machin SJ; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158: 323-35.
26. Ferrari S, Scheiflinger F, Rieger M, Mudde G, Wolf M, Coppo P, Girma JP, Azoulay E, Brun-Buisson C, Fakhouri F, Mira JP, Oksenhendler E, Poullin P, Rondeau E, Schleinitz N, Schlemmer B, Teboul JL, Vanhille P, Vernant JP, Meyer D, et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007; 109: 2815-22.
27. Zaman Z, de Spiegeleer S, Gerits M, Blanckaert N. Analytical and clinical performance of two cardiac troponin I immuno-assays. Clin Chem Lab Med 1999; 37: 889-97.
28. Collinson PO, Stubbs PJ, Kessler AC. Multicentre evaluation of the diagnostic value of cardiac troponin T, CK-MB mass, and myoglobin for assessing patients with suspected acute coronary syndromes in routine clinical practice. Heart 2003; 89: 280-6.
29. McCarthy LJ, Danielson CF, Skipworth EM, Peters SL, Miraglia CC, Antony AC. Myocardial infarction/injury is relatively common at presentation of acute thrombotic thrombocytopenic purpura: the Indiana University experience. Ther Apher 2002; 6: 2-4.
30. Di Angelantonio E, Fiorelli M, Toni D, Sacchetti ML, Lorenzano S, Falcou A, Ciarla MV, Suppa M, Bonanni L, Bertazzoni G, Aguglia F, Argentino C. Prognostic significance of admission levels of troponin I in patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry 2005; 76: 76-81.
31. Anders B, Alonso A, Artemis D, Schäfer A, Ebert A, Kablau M, Fluechter S, Findeisen P, Hennerici MG, Fatar M. What does elevated high-sensitive troponin I in stroke patients mean: concomitant acute myocardial infarction or a marker for high-risk patients? Cerebrovasc Dis 2013; 36: 211-17.
32. Nguyen L, Li X, Duvall D, Terrell DR, Vesely SK, George JN. Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006. Transfusion 2008; 48: 349-57.
33. Jilma-Stohlawetz P, Gorczyca ME, Jilma B, Siller-Matula J, Gilbert JC, Knöbl P. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost 2011; 105: 545-52.
34. Holz JB. The TITAN trial - assessing the efficacy and safety of an anti-von Willebrand factor nanobody in patients with acquired thrombotic thrombocytopenic purpura. Transfus Apher Sci 2012; 46: 343-6.
35. Tutarel O, Golla P, Beutel G, Bauersachs J, David S, Schmidt BM, Lichtinghagen R, Kielstein JT. Therapeutic plasma exchange decreases levels of routinely used cardiac and inflammatory biomarkers. PLoS ONE 2012; 7: e38573.